* The trial met its primary endpoint and key secondary endpoints, with a favorable safety profile...
* HanAll will invest in Interon Laboratories, a preclinical-stage biotechnology company focused o...
* Full-Year 2022 net revenue of KRW 110 billion, up 8% over 2021 reaching a record high * Stron...
* Financial results for Q3 2022 ended with revenue of KRW 29.6 billion with continued growth in t...
* Harbour BioMed, HanAll's licensed partner in China, signed a sublicense agreement with CSPC NBP...
* Immunovant, a HanAll's licensed partner, unveiled its plan to develop a new FcRn inhibitor, HL1...
* Financial performance for Q2 2022 records revenues of KRW 26.2 billion, a 12% growth from the s...
* HanAll will expand R&D investments to advance its late-stage pipeline assets SEOUL, South Kor...